Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...
A 12-storey office tower development backed by AFL legend Nick Riewoldt has encountered an obstacle, with construction no longer set to go ahead this month as originally planned. The $40m tower ...
Bio-Techne Corp. TECH recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results